Scienion said this week that it will provide protein microarray batches of more than 1,000 arrays to Protagen for that company's clinical validation studies of its protein biomarker panels.

According to Protagen chief scientific officer Peter Schulz-Knappe, the microarray batches will be used in "multicenter, clinical validation studies" of the company's protein biomarker panels for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.